<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy R Sterling, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Bernardo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to monitoring patients with human immunodeficiency virus (HIV) infection on antituberculous medications must include consideration of the antituberculous regimen, the antiretroviral therapy regimen, potential drug reactions, and complications related to the immune reconstitution inflammatory syndrome.
        </p>
        <p>
         This topic will cover the issues related to monitoring of patients with HIV infection with tuberculosis (TB), including directly observed therapy, the clinical response to treatment, adverse events related to treatment, duration of treatment, and prognosis.
        </p>
        <p>
         Issues related to clinical manifestations, diagnosis, and treatment of susceptible TB in patients with HIV infection are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2274974346">
         <span class="h1">
          INITIATION OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to selection of antituberculous therapy and antiretroviral therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1758484531">
         <span class="h1">
          DURATION OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regimens for treatment of TB in patients with HIV infection are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Regimen selection'
         </a>
         .)
        </p>
        <p>
         All patients with HIV infection should be started on antiretroviral therapy (ART) during treatment of tuberculosis. Issues related to timing of therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Timing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1118954907">
         <span class="h2">
          Traditional regimen (≥6 months)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of therapy for treatment of drug-susceptible pulmonary TB in patients with HIV infection on ART using the traditional regimen is six months. This includes an intensive phase of four drugs (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , a rifamycin [eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ],
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ) administered for two months, followed by a continuation phase of two drugs (isoniazid and a rifamycin) administered for four months [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         In rare instances in which ART is not administered during antituberculous therapy (ie, if ART is not available or if there are unavoidable concerns regarding drug interactions), the continuation phase of traditional antituberculous therapy should be extended for an additional three months (ie, a continuation phase of seven months, corresponding to a total of nine months of antituberculous therapy); data to support this approach are limited [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Further study is needed to address the optimal duration of antituberculous therapy in patients with HIV infection treated with the standard/traditional six-month regimen. In a 2012 meta-analysis including 6 randomized trials and 21 cohort studies, relapse was more common among patients whose regimens included two months of rifamycin than among patients whose regimens included at least eight months of rifamycin (adjusted risk ratio 5.0, 95% CI 1.9-13.2). The risk of relapse was lower with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         treatment for ≥9 months compared with 6 months of rifampin (pooled risk difference -9.1 percent, 95% CI -16.5 to -1.8 percent) [
         <a href="#rid3">
          3,4
         </a>
         ]. However, available ART has improved substantially since this study was performed [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         For patients with cavitary disease and positive sputum cultures after two months of treatment, the duration of the continuation phase should be extended from four to seven months (total duration of treatment extended from six to nine months) [
         <a href="#rid1">
          1,2
         </a>
         ]. No further adjustments in duration of therapy are recommended for patients who did not receive ART during antituberculous therapy (ie, total duration of antituberculous therapy nine months).
        </p>
        <p class="headingAnchor" id="H3431136622">
         <span class="h2">
          Rifapentine-moxifloxacin-based (4-month) regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of therapy for treatment with the rifapentine-moxifloxacin-based regimen is four months. This regimen is a potential alternative regimen for patients &gt;12 years and CD4 &gt;100 cells/microL with pulmonary TB. Use of the shortened regimen requires additional attention to drug interactions of ART as well as more intricate and detailed programmatic considerations. The regimen includes
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , high-dose
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         daily for an eight-week intensive phase followed by a continuation phase of daily isoniazid, high-dose rifapentine, and moxifloxacin for nine weeks [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         .)
        </p>
        <p>
         Completion of the regimen consists of 119 doses (56 intensive phase doses and 63 continuation phase doses). The intensive phase doses should be administered within 70 days from treatment initiation, and the continuation phase doses should be administered within 84 days from intensive phase completion [
         <a href="#rid6">
          6
         </a>
         ]. If these targets are not met, the patient should be considered to have interrupted therapy [
         <a href="#rid1">
          1,6
         </a>
         ].
        </p>
        <p>
         Thus far, circumstances in which treatment duration should be extended have not been addressed by the available trial data [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3728625240">
         <span class="h2">
          Treatment failure and relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the traditional regimen, treatment failure refers to positive sputum cultures after four months of antituberculous therapy; for the rifapentine-moxifloxacin-based regimen, lack of improvement at eight weeks should prompt re-evaluation of the patient and the treatment regimen.
        </p>
        <p>
         Relapse refers to recurrent TB at any time after completion of treatment with apparent or confirmed cure. If treatment failure or relapse is suspected or confirmed, the
         <em>
          Mycobacterium tuberculosis
         </em>
         isolate should be sent for drug susceptibility testing to first- and second-line agents. (See
         <a class="local">
          'Patients with inadequate clinical response'
         </a>
         below.)
        </p>
        <p>
         Issues related to duration of therapy for patients with HIV infection and drug-resistant TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3288296675">
         <span class="h1">
          CLINICAL MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV infection with TB generally respond well to therapy if the diagnosis is made promptly and standard therapy instituted. Fever usually resolves within one month; improvement in chest radiograph findings may take longer. Lack of weight gain during the first two months of TB treatment predicts poor treatment outcomes, independent of HIV status [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H856245311">
         <span class="h2">
          Sputum monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sputum should be obtained for acid-fast bacilli (AFB) smear and culture at monthly intervals until two consecutive cultures are negative  (
         <a class="graphic graphic_algorithm graphicRef132653" href="/z/d/graphic/132653.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef132654" href="/z/d/graphic/132654.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef132655" href="/z/d/graphic/132655.html" rel="external">
          algorithm 3
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Sputum AFB smear and culture after two months of treatment is particularly important for assessing relapse risk and for determining the duration of the continuation phase. A positive sputum culture at two months should prompt drug susceptibility testing of that
         <em>
          M. tuberculosis
         </em>
         isolate and a search for reasons for persistently positive sputum cultures, including poor adherence or malabsorption [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The approach in the setting of persistently positive sputum culture is discussed below. (See
         <a class="local">
          'Persistently positive sputum culture'
         </a>
         below.)
        </p>
        <p>
         After the sputum smear has converted to negative, at least one sputum should be collected at the completion of therapy to confirm that the patient has remained smear and culture negative [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2848278702">
         <span class="h2">
          Drug-related side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antituberculous drugs are associated with a broad array of adverse effects, and the likelihood of adverse effects may be increased in patients with HIV infection [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Patient education regarding symptoms of hepatitis and other possible drug toxicities should be reinforced at each return visit, at least monthly. Patients should be instructed to report signs or symptoms of toxicity immediately and stop antituberculous medications until advised to resume treatment.
        </p>
        <p>
         Issues related to adverse effects associated with antituberculous drugs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Manifestations and their management'
         </a>
         .)
        </p>
        <p>
         Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'
         </a>
         .)
        </p>
        <p>
         It may be beneficial to check liver function tests after two weeks of antituberculous therapy for early detection of toxicity [
         <a href="#rid9">
          9
         </a>
         ]. Thereafter, patients with HIV infection who warrant serial liver function test monitoring may be followed monthly.
        </p>
        <p>
         Issues related to regimen adjustment for drug intolerance and management of hepatotoxicity associated with antituberculous therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen adjustments for drug intolerance'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          Isoniazid
         </a>
         is associated with peripheral neuropathy; the risk may be further increased in patients with diabetes mellitus or alcohol abuse.
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          Vitamin B6
         </a>
         decreases the risk of peripheral neuropathy.
        </p>
        <p class="headingAnchor" id="H1868326374">
         <span class="h2">
          Therapeutic drug monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic drug monitoring need not be performed routinely. Drug concentration monitoring may be useful for patients with advanced HIV, diabetes, alcohol abuse, slow response to therapy (eg, positive sputum smear or culture after two months of therapy), and/or in the setting of potential for drug-drug interactions [
         <a href="#rid10">
          10-12
         </a>
         ]. Among more than 260 patients with TB and HIV infection TB in Uganda, low levels of
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         were associated with delayed sputum culture conversion, but did not translate to a high proportion of patients with treatment failure [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Issues related to drug monitoring are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Serum drug concentration monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PATIENTS WITH INADEQUATE CLINICAL RESPONSE
         </span>
        </p>
        <p class="headingAnchor" id="H3793220151">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inadequate clinical response or clinical deterioration in an patients with HIV and TB infection may be attributable to poor adherence, poor drug absorption, emergence of drug resistance, an intercurrent opportunistic infection, or the immune reconstitution inflammatory syndrome (IRIS).
        </p>
        <p>
         The approach to distinguishing between causes of inadequate clinical response depends in part on the timing relative to initiation of antituberculous therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug hypersensitivity (usually manifesting as rash or systemic reactions) generally occurs in the first few weeks of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IRIS usually occurs approximately three weeks after starting antiretroviral therapy (ART), though it can occur later. (See
         <a class="local">
          'Immune reconstitution inflammatory syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment failure is defined as positive sputum culture after four to five months of treatment. Persistently positive sputum culture may be attributable to poor adherence, poor drug absorption, and/or emergence of drug resistance. (See
         <a class="local">
          'Persistently positive sputum culture'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrence is defined as recurrent signs and symptoms after successful completion of treatment. This may be due to either relapse (with the same
         <em>
          M. tuberculosis
         </em>
         strain as the original episode) or reinfection (with a different
         <em>
          M. tuberculosis
         </em>
         strain).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intercurrent opportunistic infection is possible at any time during treatment and must be included routinely in the differential diagnosis and clinical evaluation. (See
         <a class="local">
          'Intercurrent opportunistic infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2748843968">
         <span class="h2">
          Persistently positive sputum culture
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to sputum monitoring is described above. (See
         <a class="local">
          'Sputum monitoring'
         </a>
         above.)
        </p>
        <p>
         Persistently positive sputum culture may be attributable to poor adherence, poor drug absorption, and/or emergence of drug resistance:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adherence should be reviewed; directly observed therapy should be implemented if this has not already been done. (See
         <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">
          "Adherence to tuberculosis treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapeutic drug monitoring should be pursued since poor drug absorption is common among patients with advanced HIV disease. This is particularly true in the setting of diarrhea and/or malabsorption but may occur even in the absence of these symptoms [
         <a href="#rid14">
          14-17
         </a>
         ]. Issues related to drug monitoring are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Serum drug concentration monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug susceptibility testing on a current isolate should be pursued [
         <a href="#rid1">
          1
         </a>
         ]. Patients with drug-resistant isolates should be treated as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients treated with the rifapentine-moxifloxacin-based regimen who have delayed clinical or microbiologic response with persistent positive sputum cultures beyond two months, the optimal duration of treatment is uncertain [
         <a href="#rid6">
          6
         </a>
         ]. Options (to be considered on a case-by-case basis) might include transition to the traditional or alternative regimen with extension of treatment beyond four months. In such instances, consultation with a TB expert or a CDC Center of Excellence is warranted [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1971166980">
         <span class="h2">
          Persistent symptoms and/or radiographic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Persistent symptoms and/or radiographic findings may be attributable to an intercurrent opportunistic infection, IRIS, and/or the causes of persistently positive sputum discussed in the preceding section (eg, poor adherence, poor drug absorption, and/or emergence of drug resistance).
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Intercurrent opportunistic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         New clinical findings such as fever, cough, or weight loss or new radiographic abnormalities in a patient with HIV infection on appropriate TB therapy whose sputum smear becomes negative suggest the development of an intercurrent opportunistic infection [
         <a href="#rid8">
          8
         </a>
         ]. Diagnostic considerations include
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia, pneumonia due to other bacterial, viral, or fungal causes, and lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Immune reconstitution inflammatory syndrome
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Clinical and/or radiographic deterioration despite appropriate antituberculous chemotherapy may reflect IRIS, a paradoxical worsening of a pre-existing inflammatory process following immune recovery associated with administration of ART [
         <a href="#rid19">
          19-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients with TB, IRIS has been described in 8 to 43 percent of cases [
         <a href="#rid19">
          19,21,25,26
         </a>
         ]. The risk is increased in patients with an initial CD4 count &lt;100/microL [
         <a href="#rid25">
          25
         </a>
         ] and in patients with a significant reduction in viral load and a large increase in CD4 count [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         IRIS usually occurs approximately three weeks after starting ART, though it can occur later. Clinical manifestations of IRIS in patients with HIV infection with TB include new or expanding lymph nodes or abscesses, enlarging intracranial tuberculomas, persistent pyrexia, worsening pulmonary infiltrates, and new serositis [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – IRIS is usually self-limited and in general does not require alteration or interruption of the antituberculous or antiretroviral regimens. For IRIS causing significant symptoms, treatment should be undertaken only after a thorough evaluation to exclude other potential causes of clinical deterioration. Initial management consists of nonsteroidal anti-inflammatory drugs, if symptoms persist, a short course of corticosteroids is warranted [
         <a href="#rid2">
          2
         </a>
         ]. For patients with symptoms refractory to corticosteroids, some case reports have described use of tumor necrosis factor-alpha inhibitors [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For management of symptomatic involvement such as impingement of the airway or major vessel (eg, vena cava) by enlarged mediastinal lymph nodes, use of corticosteroids (
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg orally per day) is reasonable. The dose should be tapered as symptoms allow; worsening of symptoms with tapering should prompt reversion to a higher dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with IRIS that is not responsive to corticosteroids, particularly patients with neurological manifestations of TB, tumor necrosis factor alpha inhibitors may be a useful treatment tool; further clinical data are needed [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Issues related to timing of ART to minimize the likelihood of IRIS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Timing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Issues related to prevention of TB-associated IRIS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Preventing IRIS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV infection and drug-sensitive tuberculosis generally respond well to therapy if the diagnosis is made promptly and standard therapy instituted. Fever usually resolves within one month and the chest radiograph typically improves at two to three months [
         <a href="#rid8">
          8,30,31
         </a>
         ]. In a series published prior to the antiretroviral therapy (ART) era including 82 patients with HIV infection and drug-susceptible TB, treatment failure occurred in only 5 percent of cases; all failures were attributable to poor adherence [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Treatment for drug-susceptible TB in patients with HIV infection is associated with rates of culture conversion and completion of therapy comparable to rates in HIV-uninfected patients [
         <a href="#rid1">
          1,33
         </a>
         ]. This was illustrated in an observational study of 280 patients with TB; patients whose HIV status was positive, negative, and unknown had relapse rates of 6.0, 5.5, and 3.0 percent, respectively [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         ART has significantly decreased mortality related to TB; this is most evident in resource-limited settings where TB is endemic. In a prospective study in Thailand including 290 patients with HIV infection and TB, survival was more likely among patients who received ART than those who did not (7 versus 43 percent) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Treatment for HIV infection appears to be as effective in the HIV/TB coinfected patients as in patients with HIV alone. This was illustrated in an observational study including 111 patients with HIV and TB and 45 patients with HIV infection in the absence of concomitant TB (matched for gender, ethnicity, and baseline CD4 cell count) [
         <a href="#rid36">
          36
         </a>
         ]. Viral suppression was achieved at six months in similar proportions of HIV/TB-coinfected patients and patients with HIV alone (87 versus 88 percent). Similar improvements in CD4 cell counts were also noted between patients with HIV and TB infection and patients with HIV infection in the absence of TB (97 versus 89 cells/microL). Most patients in the study were taking a nonnucleoside reverse transcriptase inhibitor along with two nucleoside analogs.
        </p>
        <p class="headingAnchor" id="H3454422568">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The approach to monitoring patients with HIV infection and pulmonary tuberculosis (TB) on antituberculous medications must include consideration of the antituberculous regimen, the antiretroviral therapy (ART) regimen, potential drug reactions, and complications related to the immune reconstitution inflammatory syndrome (IRIS). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Issues related to selection of antituberculous therapy and antiretroviral therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duration of therapy (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The traditional duration of therapy for treatment of drug-susceptible pulmonary TB in patients with HIV infection on ART is six months. This includes an intensive phase of four drugs (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , a rifamycin [eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ],
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ) administered for two months, followed by a continuation phase of two drugs (isoniazid and a rifamycin) administered for four months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The duration of therapy for the rifapentine-moxifloxacin-based regimen is four months. The regimen includes
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , high-dose
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         daily for an eight-week intensive phase followed by a continuation phase of daily isoniazid, high-dose rifapentine, and moxifloxacin for nine weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In rare instances in which ART is not administered during antituberculous therapy (ie, ART is not available or there are unavoidable concerns regarding drug interactions), the continuation phase should be extended for an additional three months (ie, a continuation phase of seven months), corresponding to a total of nine months of antituberculous therapy. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During treatment of pulmonary TB, sputum should be obtained for acid-fast bacilli (AFB) smear and culture at monthly intervals until two consecutive cultures are negative. Sputum AFB smear and culture after two months of treatment is particularly important for assessing relapse risk and for determining the duration of the continuation phase  (
         <a class="graphic graphic_algorithm graphicRef132653" href="/z/d/graphic/132653.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef132654" href="/z/d/graphic/132654.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef132655" href="/z/d/graphic/132655.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="local">
          'Sputum monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient education regarding symptoms of hepatitis and other possible drug toxicities should be reinforced at each follow-up visit, at least monthly. Patients should be instructed to report signs or symptoms of toxicity immediately and stop antituberculous medications until advised to resume. (See
         <a class="local">
          'Drug-related side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Issues related to adverse effects and laboratory monitoring for patients on antituberculous drugs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Manifestations and their management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Issues related to regimen adjustment for drug intolerance and management of hepatotoxicity associated with antituberculous therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen adjustments for drug intolerance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate clinical response or clinical deterioration in an patients with HIV infection and TB may be attributable to poor adherence, poor drug absorption, emergence of drug resistance, an intercurrent opportunistic infection, or the immune reconstitution inflammatory syndrome. (See
         <a class="local">
          'Patients with inadequate clinical response'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on April 12, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peetluk LS, Rebeiro PF, Cordeiro-Santos M, et al. Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. J Infect Dis 2020; 221:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 2012; 185:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekaggya-Wiltshire C, von Braun A, Lamorde M, et al. Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clin Infect Dis 2018; 67:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16:717.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. TB Centers of Excellence for Training, Education, and Medical Consultation. https://www.cdc.gov/tb/education/tb_coe/default.htm (Accessed on April 06, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navas E, Martín-Dávila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hachisu Y, Koga Y, Kasama S, et al. Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients. J Clin Med 2019; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu DC, Faldetta KF, Pei L, et al. A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clin Infect Dis 2016; 62:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armange L, Lacroix A, Petitgas P, et al. The use of TNF-α antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature review. Eur J Clin Microbiol Infect Dis 2023; 42:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis 1992; 15:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsburgh CR Jr, Barry CE 3rd, Lange C. Treatment of Tuberculosis. N Engl J Med 2015; 373:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193:1437.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8030 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20353364" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22820541" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33951360" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31724035" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647985" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22198973" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A comparison between two strategies for monitoring hepatic function during antituberculous therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24846578" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Therapeutic drug monitoring in the treatment of tuberculosis: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19432554" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23901086" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29514175" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8876848" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Low antituberculosis drug concentrations in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9265429" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16267738" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8866188" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Therapeutic drug monitoring of the antimycobacterial drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8866188" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Therapeutic drug monitoring of the antimycobacterial drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9655723" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10628452" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18652998" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22944873" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578375" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255740" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15478074" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11784229" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31905985" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment with Tumor Necrosis Factor-αInhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26394669" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36795280" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The use of TNF-αantagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1520806" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26605929" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Treatment of Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7952606" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10051244" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10513648" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18214171" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16619192" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
